Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

October 31, 2010

Conditions

Melanoma

Interventions

DRUG

TLN-232

21 day continuous IV administration of TLN-232 followed by a 7-day recovery period

Trial Locations (4)

Fox Chase Cancer Center, Philadelphia

Juravinski Cancer Centre, Hamilton

Princess Margaret Hospital, Toronto

Hôpital Notre-Dame du CHUM, Montreal